VAXART, INC. Appoints Ray Stapleton as Chief Technology Officer

September 1, 2022

Trending News 🌥️

Vaxart, Inc. Intrinsic Value – Ray Stapleton has been appointed as Chief Technology Officer at Vaxart,($NASDAQ:VXRT) effective immediately. Prior to this appointment, Dr. Stapleton served as CTO and Executive Vice President at Genocea, working to develop next-generation personalized immunotherapies in the forms of vaccines and cell therapies. Dr. Stapleton’s experience in developing innovative immunotherapies will be a valuable asset to Vaxart as the company looks to continue advancing its own vaccine and cell therapy programs. This appointment could have a positive impact on Vaxart’s market and earnings in the long term, as Dr. Stapleton’s expertise could help to further improve the company’s product offerings.

Share Price

VAXART, INC. stock opened at $3.0 and closed at $3.1, up by 3.7% from last closing price of 3.0.

VI Analysis – Vaxart, Inc. Intrinsic Value

VAXART, INC. is a clinical-stage biotechnology company focused on developing oral recombinant vaccines. Its proprietary technology platforms are based on live, attenuated, double-deleted virus-like particles and baculovirus expression vector system . The company’s technology platforms are designed to induce broad and durable immune responses against a range of infectious diseases, as well as cancer and other diseases. VaxArt is also developing vaccine candidates against seasonal influenza, norovirus and human papillomavirus . The intrinsic value of VAXART, INC. share is around $4.5, calculated by VI Line. Now VAXART, INC. stock is traded at $3.1, undervalued by 32%.


VAXART, INC. is a clinical-stage biotechnology company focused on the development and commercialization of oral recombinant vaccines. The Company’s technology is based on its proprietary platform, which is designed to produce non-infectious virus-like particles in a tablet form that can be used for oral vaccination. The Company’s products in development include vaccines against influenza, norovirus and human papillomavirus . Mr. Prior to joining VAXART, he served as Senior Vice President of Research & Development at PaxVax, where he played a key role in the development and commercialization of the company’s oral cholera vaccine, Vaxchora. This appointment signals the company’s commitment to continue developing its novel vaccine technology and advancing its clinical programs. With an experienced executive like Mr. Stapleton at the helm, VAXART is well positioned to bring its innovative products to market and drive shareholder value.

Recent Posts

Leave a Comment